MX2017003049A - Administracion dirigida de farmacos hidrofilicos. - Google Patents
Administracion dirigida de farmacos hidrofilicos.Info
- Publication number
- MX2017003049A MX2017003049A MX2017003049A MX2017003049A MX2017003049A MX 2017003049 A MX2017003049 A MX 2017003049A MX 2017003049 A MX2017003049 A MX 2017003049A MX 2017003049 A MX2017003049 A MX 2017003049A MX 2017003049 A MX2017003049 A MX 2017003049A
- Authority
- MX
- Mexico
- Prior art keywords
- aqueous
- targeted delivery
- hydrophilic drugs
- particles
- production
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000000084 colloidal system Substances 0.000 abstract 2
- 201000007270 liver cancer Diseases 0.000 abstract 2
- 208000014018 liver neoplasm Diseases 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241000168096 Glareolidae Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 239000003560 cancer drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1400427 | 2014-09-10 | ||
| PCT/SE2015/000055 WO2016039678A1 (en) | 2014-09-10 | 2015-09-09 | Targeted delivery of hydrophilic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017003049A true MX2017003049A (es) | 2017-05-23 |
Family
ID=55459328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003049A MX2017003049A (es) | 2014-09-10 | 2015-09-09 | Administracion dirigida de farmacos hidrofilicos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10034838B2 (enExample) |
| EP (1) | EP3191138B1 (enExample) |
| JP (1) | JP6951971B2 (enExample) |
| KR (1) | KR20170054459A (enExample) |
| CN (1) | CN107073129B (enExample) |
| AU (1) | AU2015316252A1 (enExample) |
| CA (1) | CA2958820A1 (enExample) |
| EA (1) | EA033526B1 (enExample) |
| IL (1) | IL250637A0 (enExample) |
| MX (1) | MX2017003049A (enExample) |
| WO (1) | WO2016039678A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3426228A1 (en) * | 2016-03-07 | 2019-01-16 | Double Bond Pharmaceutical AB | Targeted delivery of hydrophilic drugs to lung |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| CA2324254C (en) * | 1998-03-18 | 2005-01-04 | University Technology Corporation | Sustained-release composition including amorphous polymer |
| US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6384081B2 (en) * | 1998-10-09 | 2002-05-07 | Charles L. Berman | Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| CN101134119A (zh) | 2002-05-24 | 2008-03-05 | 血管技术国际股份公司 | 用于涂覆医用植入物的组合物和方法 |
| US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
| US20040161466A1 (en) | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| GB2415904B (en) | 2005-02-07 | 2006-10-25 | Chiron Corp | Preparing aldesleukin for pharmaceutical use |
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009100222A1 (en) | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
| CN101327190B (zh) * | 2008-07-29 | 2011-04-27 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
| KR101576174B1 (ko) * | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| KR101728011B1 (ko) | 2013-01-23 | 2017-04-20 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 덱스트란 메타크릴레이트 및 생체적합성 음이온성 고분자를 포함하는 생분해성 마이크로 비드 및 이의 제조방법 |
-
2015
- 2015-09-09 KR KR1020177009510A patent/KR20170054459A/ko not_active Withdrawn
- 2015-09-09 AU AU2015316252A patent/AU2015316252A1/en not_active Abandoned
- 2015-09-09 EA EA201790272A patent/EA033526B1/ru not_active IP Right Cessation
- 2015-09-09 US US15/509,875 patent/US10034838B2/en active Active
- 2015-09-09 MX MX2017003049A patent/MX2017003049A/es unknown
- 2015-09-09 CN CN201580048892.5A patent/CN107073129B/zh active Active
- 2015-09-09 CA CA2958820A patent/CA2958820A1/en not_active Abandoned
- 2015-09-09 EP EP15840525.8A patent/EP3191138B1/en active Active
- 2015-09-09 JP JP2017514562A patent/JP6951971B2/ja active Active
- 2015-09-09 WO PCT/SE2015/000055 patent/WO2016039678A1/en not_active Ceased
-
2017
- 2017-02-16 IL IL250637A patent/IL250637A0/en unknown
-
2018
- 2018-07-17 US US16/037,429 patent/US10973772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3191138A4 (en) | 2018-06-20 |
| IL250637A0 (en) | 2017-04-30 |
| JP2017527593A (ja) | 2017-09-21 |
| JP6951971B2 (ja) | 2021-10-20 |
| EP3191138A1 (en) | 2017-07-19 |
| CA2958820A1 (en) | 2016-03-17 |
| EP3191138B1 (en) | 2024-05-29 |
| EA033526B1 (ru) | 2019-10-31 |
| US10034838B2 (en) | 2018-07-31 |
| WO2016039678A1 (en) | 2016-03-17 |
| US20170239192A1 (en) | 2017-08-24 |
| US20190046462A1 (en) | 2019-02-14 |
| KR20170054459A (ko) | 2017-05-17 |
| EP3191138C0 (en) | 2024-05-29 |
| CN107073129A (zh) | 2017-08-18 |
| CN107073129B (zh) | 2021-10-15 |
| AU2015316252A1 (en) | 2017-03-09 |
| US10973772B2 (en) | 2021-04-13 |
| EA201790272A1 (ru) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002308A1 (es) | Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer | |
| PH12017502155A1 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| MX2021007794A (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| WO2016145008A3 (en) | Mirna for treatment of breast cancer | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| MX2019003988A (es) | Formulaciones de nanoparticulas y sus metodos de fabricacion y uso. | |
| WO2017017063A3 (en) | Nanoparticle-based liver-targeting therapy and imaging | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| WO2016011049A3 (en) | Compositions and methods for disease treatment using nanoparticle delivered compounds | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| ZA201700922B (en) | Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer | |
| SMT202200275T1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione | |
| SG10201902499VA (en) | Therapeutic nanoparticles and related compositions, methods and systems | |
| MX395613B (es) | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. | |
| EP3178786A3 (en) | Graphene oxide nanoparticle compositions and methods of making the same | |
| MX2016005900A (es) | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. | |
| GB2551453A (en) | Nanocarrier delivery system for hydrophobic substances | |
| EA033526B1 (ru) | Адресная доставка гидрофильных лекарственных средств | |
| AR107829A1 (es) | Monotartrato de vinorelbina y su uso farmacéutico |